Literature DB >> 8923469

Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes.

A Staal1, A J van Wijnen, J C Birkenhäger, H A Pols, J Prahl, H DeLuca, M P Gaub, J B Lian, G S Stein, J P van Leeuwen, J L Stein.   

Abstract

The 1 alpha,25-dihydroxyvitamin D3 (VD3)-dependent stimulation of osteocalcin (OC) and osteopontin (OP) gene transcription in bone tissue is mediated by interactions of trans-activating factors with distinct VD3-responsive elements (VDREs). Sequence variation between the OC- and OP-VDRE steroid hormone half-elements provides the potential for recognition by distinct hormone receptor homo- and heterodimers. However, the exact composition of endogenous VD3- induced complexes recognizing the OC- and OP-VDREs in osteoblasts has not been definitively established. To determine the identity of these complexes, we performed gel shift immunoassays with nuclear proteins from ROS 17/ 2.8 osteoblastic cells using a panel of monoclonal antibodies. We show that VD3- inducible complexes interacting with the OC- and OP-VDREs represent two distinct heterodimeric complexes, each composed of the vitamin D receptor (VDR) and the retinoid X receptor-alpha (RXR). The OC- and OP-VDR/RXR alpha heterodimers are immunoreactive with RXR antibodies and several antibodies directed against the ligand-binding domain of the VDR. However, while the OC-VDRE complex is also efficiently recognized by specific monoclonal antibodies contacting epitopes in or near the VDR DNA-binding domain (DBD) (between amino acids 57-164), the OP-VDRE complex is not efficiently recognized by these antibodies. By systematically introducing a series of point-mutations in the OC-VDRE, we find that two internal nucleotides of the proximal OC-VDRE half-site (nucleotide -449 and -448; 5'-AGGACA) determine differences in VDR immunoreactivity. These results are consistent with the well established polarity of RXR heterodimer binding to bipartite hormone response elements, with the VDR recognizing the 3'-half-element. Furthermore, our data suggest that the DBD of the VDR adopts different protein conformations when contacting distinct VDREs. Distinctions between the OC- and OP-VDR/RXR alpha complexes may reflect specialized requirements for VD3 regulation of OC and OP gene expression in response to physiological cues mediating osteoblast differentiation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923469     DOI: 10.1210/mend.10.11.8923469

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  17 in total

1.  Asymmetric recognition of nonconsensus AP-1 sites by Fos-Jun and Jun-Jun influences transcriptional cooperativity with NFAT1.

Authors:  Vladimir Ramirez-Carrozzi; Tom Kerppola
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

Review 2.  Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.

Authors:  Consuelo Buttigliero; Chiara Monagheddu; Paola Petroni; Andrea Saini; Luigi Dogliotti; Giovannino Ciccone; Alfredo Berruti
Journal:  Oncologist       Date:  2011-08-11

3.  1alpha,25-dihydroxy vitamin D(3) induces nuclear matrix association of the 1alpha,25-dihydroxy vitamin D(3) receptor in osteoblasts independently of its ability to bind DNA.

Authors:  Gloria Arriagada; Roberto Paredes; Andre J van Wijnen; Jane B Lian; Brigitte van Zundert; Gary S Stein; Janet L Stein; Martin Montecino
Journal:  J Cell Physiol       Date:  2010-02       Impact factor: 6.384

4.  Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression.

Authors:  Jae Young So; Joseph E Wahler; Taesook Yoon; Amanda K Smolarek; Yong Lin; Weichung Joe Shih; Hubert Maehr; Milan Uskokovic; Karen T Liby; Michael B Sporn; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-15

5.  YY1 regulates vitamin D receptor/retinoid X receptor mediated transactivation of the vitamin D responsive osteocalcin gene.

Authors:  B Guo; F Aslam; A J van Wijnen; S G Roberts; B Frenkel; M R Green; H DeLuca; J B Lian; G S Stein; J L Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

6.  All natural DR3-type vitamin D response elements show a similar functionality in vitro.

Authors:  A Toell; P Polly; C Carlberg
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

7.  Interaction of the 1alpha,25-dihydroxyvitamin D3 receptor at the distal promoter region of the bone-specific osteocalcin gene requires nucleosomal remodelling.

Authors:  Roberto Paredes; José Gutiérrez; Soraya Gutierrez; Lizabeth Allison; Marcia Puchi; Maria Imschenetzky; Andre van Wijnen; Jane Lian; Gary Stein; Janet Stein; Martin Montecino
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

Review 8.  An architectural perspective of vitamin D responsiveness.

Authors:  Martin Montecino; Gary S Stein; Fernando Cruzat; Sylvain Marcellini; Janet L Stein; Jane B Lian; Andre J van Wijnen; Gloria Arriagada
Journal:  Arch Biochem Biophys       Date:  2007-01-08       Impact factor: 4.013

9.  Bone-specific transcription factor Runx2 interacts with the 1alpha,25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells.

Authors:  Roberto Paredes; Gloria Arriagada; Fernando Cruzat; Alejandro Villagra; Juan Olate; Kaleem Zaidi; Andre van Wijnen; Jane B Lian; Gary S Stein; Janet L Stein; Martin Montecino
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

10.  Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer.

Authors:  Rebecca Suk Heist; Wei Zhou; Zhaoxi Wang; Geoffrey Liu; Donna Neuberg; Li Su; Kofi Asomaning; Bruce W Hollis; Thomas J Lynch; John C Wain; Edward Giovannucci; David C Christiani
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.